NCT02728388View on ClinicalTrials.gov

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
NEUROFIBROMATOSIS 1
Interventions
DRUG

aminolevulinic acid

"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"

Trial Locations (1)

53226

RECRUITING

Donald G Basel, Milwaukee

All Listed Sponsors
lead

Donald Basel

OTHER

NCT02728388 - Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | Biotech Hunter | Biotech Hunter